GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Issuance of Stock

CVKD (Cadrenal Therapeutics) Issuance of Stock : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Issuance of Stock?

Cadrenal Therapeutics's Issuance of Stock for the three months ended in Dec. 2024 was $0.00 Mil.

Cadrenal Therapeutics's Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Cadrenal Therapeutics Issuance of Stock Historical Data

The historical data trend for Cadrenal Therapeutics's Issuance of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Issuance of Stock Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
Issuance of Stock
- 11.90 5.14

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Issuance of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 - - - -

Cadrenal Therapeutics Issuance of Stock Calculation

A company may raise cash from issuing new shares. Issuance of Stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Issuance of Stock for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Issuance of Stock Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Issuance of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Issuance of Stock
Comparable Companies
FBLG ALXO KPTI NRXP OSTX LVTX RNXT TPST AKTX SRZN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Website
https://www.cadrenal.com
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029